Key result
A single 10 mg oral dose of enalapril maleate significantly lowered mean blood pressure in both low-renin and normal/high-renin hypertensive patients, with maximal reduction occurring at 4 hours post-administration.
Why the study?
Does a single oral dose of enalapril maleate acutely reduce blood pressure and alter renin-angiotensin-aldosterone and kinin systems in hypertensive patients?
Does a single oral dose of enalapril maleate acutely reduce blood pressure and alter renin-angiotensin-aldosterone and kinin systems in hypertensive patients?
p-value: p=<0.001
A single oral dose of enalapril maleate acutely lowers blood pressure in hypertensive patients through inhibition of angiotensin II formation and kinin accumulation, regardless of baseline renin levels.
Supports acute BP reduction by enalapril irrespective of renin status; hypothesis-generating and should not yet change practice.
The acute antihypertensive effect of a new long-acting oral angiotensin I-converting enzyme (ACE) inhibitor, enalapril maleate, was assessed in 20 hypertensive patients, of whom 14 had essential hypertension, 4 had renovascular hypertension, one had hypertension associated with chronic renal failure, and one had primary aldosteronism. Enalapril maleate significantly lowered the blood pressure in either low-renin or normal- and high-renin hypertensives. There was a significant correlation for all patients as a group between the pretreatment levels of serum ACE activity and the reduction in mean blood pressure (r = -0.454, p less than 0.05, n = 20) 2 h after drug administration. The serum ACE activity decreased maximally 3 to 4 hours after drug administration and did not return to baseline levels within 24 h. There was a significant correlation between the reduction in mean blood pressure and changes in ACE activity 90 min and 2 h after drug administration, respectively, for all patients as a group (r = 0.495, p less than 0.05, n = 20, at 90 min; r = 0.508, p less than 0.05, n = 20, at 2 h). The plasma renin activity (PRA) significantly increased in normal- and high-renin hypertensives but not in low-renin hypertensives. There was a close correlation between the reduction in mean blood pressure and the PRA 8 h after drug administration in normal- and high-renin patients (r = -0.623, p less than 0.05, n = 13), while no such relationship was observed in low-renin patients. The plasma aldosterone concentration (PAC) significantly decreased within 3 h, the lowest values occurring at 8 h after drug administration, and it returned to baseline levels within 24 h in all patients. No relationship was found between the reduction in mean blood pressure and changes in PAC after drug administration in either low-renin or normal- and high-renin hypertensives. The plasma bradykinin concentration (PBC) increased within 1 h, the highest values occurring at 3 h after drug administration, and returned to baseline levels within 24 h in low-renin hypertensives, while the PBC was significantly increased at 4 h and had not returned to baseline levels within 24 h in normal- and high-renin hypertensives. There was a significant correlation between percentage changes in mean blood pressure and those in PBC 90 min after drug administration in normal- and high-renin hypertensives (r = -0.556, p less than 0.05, n = 13), while no relationship was observed between them in low-renin hypertensives.(ABSTRACT TRUNCATED AT 400 WORDS)
No takes yet. Share an insight, caveat, or question.
GOTOH et al. (1985) studied Hypertension (n=20). Enalapril maleate vs. Baseline (pre-treatment) was evaluated on Reduction in mean blood pressure at 4 hours post-dose (p=<0.001). A single 10 mg oral dose of enalapril maleate significantly lowered mean blood pressure in both low-renin and normal/high-renin hypertensive patients, with maximal reduction occurring at 4 hours post-administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: